September 10, 2007 -
TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced FDA compliant testing company
AppTec, headquartered in St. Paul, Minnesota, has begun preclinical testing of its lead product, a TAP based therapeutic cancer vaccine.
The immunotherapy vaccine is designed to treat a wide variety of TAP deficient carcinomas that include
lung cancers, liver cancers, kidney cancers, head and neck cancers, breast cancers, melanomas, prostate cancers, colorectal cancers, and cervical cancers. This is the first step in the product development program that will bring the vaccine to Phase 1 Human studies...
TapImmune's Press Release -
